Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: The Ultra-Curto randomized controlled trial.
Saved in:
| Title: | Acceptability and safety of one versus three months of rifapentine and isoniazid to prevent tuberculosis in people exposed in the household or workplace in Brazil: The Ultra-Curto randomized controlled trial. |
|---|---|
| Authors: | Durovni B; Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil., Cordeiro-Santos M; Fundação de Medicina Tropical 'Doutor Heitor Vieira Dourado', Manaus, Brazil.; Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil.; Pós-Graduação em Saúde e Inovação, Universidade Nilton Lins, Manaus, Amazonas, Brazil., Cavalcante SC; Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil., Spener-Gomes R; Fundação de Medicina Tropical 'Doutor Heitor Vieira Dourado', Manaus, Brazil.; Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Brazil.; Faculdade de Medicina, Universidade Federal do Amazonas, Manaus, Brazil., Garcia J; Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil., Cohn S; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America., Saraceni V; Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, Brazil., Kohler B; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America., Moulton LH; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America., Brito da Souza A; Fundação de Medicina Tropical 'Doutor Heitor Vieira Dourado', Manaus, Brazil., Berihun A; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America., Marzinke M; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.; Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America., Chaisson RE; Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America. |
| Corporate Authors: | Ultra Curto Study Team |
| Source: | PLoS medicine [PLoS Med] 2026 Feb 10; Vol. 23 (2), pp. e1004758. Date of Electronic Publication: 2026 Feb 10 (Print Publication: 2026). |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase IV; Multicenter Study; Comparative Study |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101231360 Publication Model: eCollection Cited Medium: Internet ISSN: 1549-1676 (Electronic) Linking ISSN: 15491277 NLM ISO Abbreviation: PLoS Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1549-1676 |
|---|---|
| DOI: | 10.1371/journal.pmed.1004758 |
